Randomized phase II trial of single agent motexafin gadolinium [Xcytrin; Pharmacyclics] for second line treatment of non-small cell lung cancer

Trial Profile

Randomized phase II trial of single agent motexafin gadolinium [Xcytrin; Pharmacyclics] for second line treatment of non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2008

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 19 Aug 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Sep 2007 Results from 60 evaluable patients were presented at the 12th World Conference on Lung Cancer held in Seoul, South Korea on 2-6 September 2007.
    • 01 Jun 2007 Status changed from 'recruiting' to 'in progress'
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top